| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -9,740 | -14,676 |
| Depreciation of fixed assets | 46,999 | 31,131 |
| Allowance for doubtful accounts - accounts receivable | 2,690 | 0 |
| Stock based compensation | 48,838 | 36,629 |
| Accounts receivable | 83,483 | -42,591 |
| Inventory | 1,736 | 8,304 |
| Prepaid expenses | 30,607 | 10,614 |
| Accrued interest - related party | 22,713 | 25,142 |
| Accrued interest | 35,901 | 23,803 |
| Accounts payable | -54,748 | -37,527 |
| Accrued liabilities | -29,858 | -68,726 |
| Changes in discontinued operations, net | 328 | 275 |
| Cash (used in) provided by operating activities | -52,703 | 19,724 |
| Purchase of fixed assets | 3,619 | 3,618 |
| Sale of fixed assets | 842 | 841 |
| Cash used in investing activities | -2,777 | -2,777 |
| Proceeds - notes payable other | 59,024 | 0 |
| Repayments - notes payable other | 44,962 | 22,895 |
| Cash provided by financing activities | 14,062 | -22,895 |
| Effect of exchange rate changes on cash | - | 0 |
| Net (decrease) increase in cash | -41,418 | -5,948 |
| Cash and cash equivalents at beginning of period | 105,648 | - |
| Cash and cash equivalents at end of period | 64,230 | - |
VYCOR MEDICAL INC (VYCO)
VYCOR MEDICAL INC (VYCO)